MediXall (MDXL) Return on Sales (2021 - 2024)
MediXall's Return on Sales history spans 4 years, with the latest figure at 6.79% for Q3 2024.
- For Q3 2024, Return on Sales rose 2065.0% year-over-year to 6.79%; the TTM value through Sep 2024 reached 7.11%, up 1369.0%, while the annual FY2023 figure was 14.75%, 10050.0% up from the prior year.
- Return on Sales reached 6.79% in Q3 2024 per MDXL's latest filing, up from 9.2% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 6.79% in Q3 2024 to a low of 407.31% in Q1 2021.
- Average Return on Sales over 4 years is 113.66%, with a median of 15.69% recorded in 2023.
- The largest YoY upside for Return on Sales was 31652bps in 2022 against a maximum downside of -14016bps in 2022.
- A 4-year view of Return on Sales shows it stood at 258.66% in 2021, then skyrocketed by 66bps to 88.05% in 2022, then surged by 83bps to 15.39% in 2023, then skyrocketed by 144bps to 6.79% in 2024.
- Per Business Quant, the three most recent readings for MDXL's Return on Sales are 6.79% (Q3 2024), 9.2% (Q2 2024), and 4.12% (Q1 2024).